Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a... see more

TSX:SVA - Post Discussion

Sernova Corp > Another SVA reviewed publication!!
View:
Post by rixpix on Jan 20, 2022 7:29am

Another SVA reviewed publication!!

More good news, but some might call it fluff. I say gimme good fluff everyday so we can be in the news. https://sernova.com/press/release/?id=329&s=09
Comment by BioTeck on Jan 20, 2022 8:54am
Nothing wrong with a good fluffing everyday but this is hardly that. There isn't much in here that wasnt presented at the end of the hemacure project over a year ago. Get it into human trials. Oh we can't because spill is still looking for patient 7. Oh and then spill has to micro manage the thyroid guy he hired to file the paperwork for a human trial. Wait 3 years for that trial to ...more  
Comment by Mercuryfilling1 on Jan 20, 2022 4:55pm
Get it into human trials. Oh we can't because spill is still looking for patient 7.  No he's not. That trial's run by Dr. Witkowski who designed the study protocol. Phil's the sponser not the searcher. Why blur the lines when you know it's up to Dr. W to find patient seven.
Comment by Stockfshr on Jan 20, 2022 5:21pm
Good point, Mercury. But to further clarify, Sernova's January 10 news release states: "A seventh study patient has been identified."
Comment by BioTeck on Jan 20, 2022 6:53pm
Many have been identified. None have been selected. Do some DD Instead of nitpicking at who's responsible for the physical searching. I'm sure Phil is heavily involved. Fluff news as per usual, nothing new and hence the price remains low. Strike one spilly spill. Battter up!
Comment by Mercuryfilling1 on Jan 20, 2022 7:33pm
Really Bio? So the President & CEO of the company sponsering the study is "heavily involved" in choosing the patient(s)? That would be just plain weird and probably unethical.
Comment by Mercuryfilling1 on Jan 20, 2022 7:45pm
...not to mention you're tarring Witkowski with the same brush, which also strikes me as weird. But hey,  carry on with your soft bash.
Comment by BioTeck on Jan 21, 2022 9:29am
Sure if you think so. Call the company and find out. I know the answer, you sound a little unsure.
Comment by Mercuryfilling1 on Jan 21, 2022 10:33am
The difference between a Sponser and a Sponser-Investigator seems pretty clear in this link: https://learn.marsdd.com/article/clinical-trials-sponsors-and-sponsor-investigators/ Feel free to post anything indicating that Philip is a "Sponser-Investigator and plays a "investigative" role in the Witkowski study. He would be obliged to publish that information.  I'm happy to ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities